NDAORAL-28TABLET
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO/OVRAL-28 is an oral contraceptive combining ethinyl estradiol (estrogen) and norgestrel (progestin) in a 28-day tablet pack. It prevents ovulation and alters cervical mucus to inhibit sperm penetration, providing contraceptive efficacy when taken daily. This combination hormone therapy has been a foundational oral contraceptive since its approval in 1976.
LOE Approaching
As a mature, off-patent oral contraceptive facing loss-of-exclusivity, this product likely operates with a lean commercial team focused on defending market share against generic competition rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LO/OVRAL-28 offers limited career growth opportunity given its mature, LOE-approaching status and minimal clinical activity. Roles focus on defensive commercial execution, generic competition mitigation, and customer relationship management rather than innovation or launch leadership.
Brand ManagerField Sales Representative
Worked on LO/OVRAL-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.